

Resource Summary Report

Generated by [NIF](#) on Aug 9, 2026

RSEM

RRID:SCR_000262

Type: Tool

Proper Citation

RSEM (RRID:SCR_000262)

Resource Information

URL: <http://deweylab.biostat.wisc.edu/rsem/>

Proper Citation: RSEM (RRID:SCR_000262)

Description: Software package for quantifying gene and isoform abundances from single end or paired end RNA Seq data. Accurate transcript quantification from RNA Seq data with or without reference genome. Used for accurate quantification of gene and isoform expression from RNA-Seq data.

Synonyms: RSEM, RNA-Seq by Expectation-Maximization, RSEM-v1.3.0

Resource Type: software resource, software application, data analysis software, data processing software

Defining Citation: [PMID:21816040](#)

Keywords: quantifying, gene, isoform, abundance, single, end, paired, RNA seq, data, transcript, reference, genome, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: RSEM

Resource ID: SCR_000262

Alternate IDs: OMICS_01966, OMICS_01287, biotools:rsem, SCR_013027

Alternate URLs: <https://github.com/deweylab/RSEM>,
<https://github.com/deweylab/RSEM/releases>, <https://bio.tools/rsem>,
<https://sources.debian.org/src/rsem/>

License: GNU GPL

License URLs: <http://www.gnu.org/copyleft/gpl.html>

Record Creation Time: 20220129T080200+0000

Record Last Update: 20260808T185713+0000

Ratings and Alerts

No rating or validation information has been found for RSEM.

No alerts have been found for RSEM.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 115 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bernard MJ, et al. (2026) OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance. Molecular cancer research : MCR, 24(5), 356.

Ding C, et al. (2026) Glioblastoma-Secreted C1QL1 Orchestrates Tumor Microtube Expansion and Neural Synaptic Pruning to Drive Malignant Synapse Formation and Recurrence. Cancer discovery, 16(6), 1176.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Li Y, et al. (2026) Dual targeting of topoisomerase I and DNA G-quadruplexes enhances senescence and chemosensitivity in colorectal cancer. Communications biology, 9(1).

Park J, et al. (2026) Innate immune priming by n-dodecyl-??-D-maltoside in murine models of bacterial and viral infection. EBioMedicine, 124, 106143.

Abdelfattah N, et al. (2026) Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. Cancer cell, 44(4), 760.

Farsi Z, et al. (2026) Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice. iScience, 29(2), 114700.

Nitsch S, et al. (2026) H4K16 acylations destabilize chromatin architecture and facilitate transcriptional response during metabolic perturbations. Molecular cell, 86(1), 24.

Sato K, et al. (2026) Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma. Cancer research communications, 6(2), 260.

- Hasegawa K, et al. (2026) Age-related decline in nuclear envelope LINC complex drives neuronal aging via axon initial segment dysfunction. *EMBO reports*, 27(13), 3788.
- Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.
- Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.
- Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. *Cancer immunology research*, 14(4), 528.
- Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.
- Swancutt KL, et al. (2026) Immune Stromal Components Impede Biological Effectiveness of Carbon Ion Therapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma. *Molecular cancer therapeutics*, 25(2), 333.
- Hofvander J, et al. (2026) Transcriptomic Subgroups in Soft Tissue Tumors Correlate with Morphologic Subtype, Genomic Features, and Outcome. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1825.
- Purohit TA, et al. (2026) Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. *Neoplasia (New York, N.Y.)*, 73, 101289.
- Yang Y, et al. (2026) PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(10), 1995.
- Monti M, et al. (2026) Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas. *Journal for immunotherapy of cancer*, 14(3).
- Williams JS, et al. (2026) Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors. *Science advances*, 12(16), eaea4966.